[EN] INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS<br/>[FR] INDAZOLE-3-CARBOXAMIDES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA VOIE DE SIGNALISATION PAR WNT/Beta-CATÉNINE
申请人:SAMUMED LLC
公开号:WO2013040215A1
公开(公告)日:2013-03-21
lndazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole-3- carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
本文披露了用于治疗各种疾病和病理的吲唑-3-羧酰胺化合物。更具体地,本文涉及使用吲唑-3-羧酰胺化合物或其类似物治疗由Wnt途径信号激活所特征的疾病(例如癌症、异常细胞增殖、血管生成和骨关节炎),调节由Wnt途径信号介导的细胞事件,以及由于Wnt途径和/或Wnt信号组分之一或多个的突变或失调而引起的遗传疾病和神经系统疾病/紊乱/疾病。还提供了治疗与Wnt相关疾病状态的方法。